Sign In
Buy LEGN
$35.98
-0.300 (-0.83%)
At Close: Jun 03, 2026
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:01am, Thursday, 19'th Dec 2024
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chi
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4
Legend Biotech: The Story Brightens
02:14pm, Thursday, 05'th Dec 2024
Legend Biotech's Carvykti, a CAR-T therapy, has shown significant sales growth since being launched in 2022. The company has some $1.2 billion in cash on its balance sheet and losses are projected to
Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript
02:45pm, Tuesday, 12'th Nov 2024
Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say
10:31am, Tuesday, 12'th Nov 2024
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with W
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Monday, 11'th Nov 2024
After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
07:30am, Thursday, 07'th Nov 2024
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, D
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
09:10am, Tuesday, 05'th Nov 2024
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
07:30am, Monday, 04'th Nov 2024
Newly created position to lead efforts focused on continued growth and sales Newly created position to lead efforts focused on continued growth and sales
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
10:55am, Thursday, 24'th Oct 2024
The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Stock Picks From Seeking Alpha's September 2024 New Analysts
08:00am, Friday, 04'th Oct 2024
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and
Legend Biotech to set up new R&D facility in Philadelphia
07:41am, Thursday, 03'rd Oct 2024
Legend Biotech said on Thursday it would set up a new research and development facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
07:30am, Thursday, 03'rd Oct 2024
New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader New 31,000 square-foot facility will enhance L
Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.
SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data
